| [1] |
Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors[J]. Pharmacol Rev，2011，63(1):182-217.
|
| [2] |
Gholipour N, Ohradanova-Repic A, Ahangari G. A novel report of MiR-4301 induces cell apoptosis by negatively regulating DRD2 expression in human breast cancer cells[J]. J Cell Biochem, 2018，119(8):6408-6417.
|
| [3] |
Andereggen L, Frey J, Andres RH, et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas[J]. Endocrine，2017，55(1):223-230.
|
| [4] |
Sarkar C, Chakroborty D, Chowdhury UR, et al. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models[J]. Clin Cancer Res，2008，14(8):2502-2510.
|
| [5] |
Costa R, Santa-Maria CA, Scholtens DM, et al. A pilot study of cabergoline for the treatment of metastatic breast cancer[J]. Breast Cancer Res Treat，2017，165(3):585-592.
|
| [6] |
Rondou P, Haegeman G, Van Craenenbroeck K. The dopamine D4 receptor: biochemical and signalling properties[J]. Cell Mol Life Sci，2010，67(12):1971-1986.
|
| [7] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin，2017，67(1):7-30.
|
| [8] |
陈万青，孙可欣，郑荣寿，等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤，2018，27(1):1-14.
|
| [9] |
Minami K, Liu S, Liu Y, et al. Inhibitory effects of dopamine receptor D1 agonist on mammary tumor and bone metastasis[J]. Sci Rep，2017，7:45686.
|
| [10] |
Pornour M, Ahangari G, Hejazi SH, et al. New perspective therapy of breast cancer based on selective dopamine receptor D2 agonist and antagonist effects on MCF-7 cell line[J]. Recent Pat Anticancer Drug Discov，2015，10(2):214-223.
|
| [11] |
Wang S, Mou Z, Ma Y, et al. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells[J]. Biochem Pharmacol，2015，95(2):98-109.
|
| [12] |
Jin X, Zou B, Luo L, et al. Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy[J]. Int J Nanomedicine，2016，11:4545-4552.
|
| [13] |
Li J, Yao QY, Xue JS, et al. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer[J]. Acta Pharmacol Sin，2017，38(9):1282-1296.
|
| [14] |
Borcherding DC, Tong W, Hugo ER, et al. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer[J]. Oncogene，2016，35(24):3103-3113.
|
| [15] |
Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer[J]. Arch Gen Psychiatry，2002，59(12):1147-1154.
|
| [16] |
Bushe CJ, Bradley AJ, Wildgust HJ, et al. Schizophrenia and breast cancer incidence: a systematic review of clinical studies[J]. Schizophr Res，2009，114(1-3):6-16.
|
| [17] |
Pornour M, Ahangari G, Hejazi SH, et al. Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer[J]. Asian Pac J Cancer Prev，2014，15(23):10339-10343.
|
| [18] |
Akbari ME, Kashani FL, Ahangari G, et al. The effects of spiritual intervention and changes in dopamine receptor gene expression in breast cancer patients[J]. Breast Cancer，2016，23(6):893-900.
|
| [19] |
Bakhtou H, Olfatbakhsh A, Deezagi A, et al. The expression of dopamine receptors gene and their potential role in targeting breast cancer cells with selective agonist and antagonist drugs. Could it be the novel insight to therapy？[J]. Curr Drug Discov Technol, 2019，16(2):184-197.
|
| [20] |
盛湲，李恒宇. 从单细胞水平看肿瘤异质性[J/CD]. 中华乳腺病杂志(电子版)，2014，8(6):6-12.
|
| [21] |
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med，1997，3(7):730-737.
|
| [22] |
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell，2011，144(5):646-674.
|
| [23] |
Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype[J]. J Clin Pathol，2011，64(11):937-946.
|
| [24] |
Sachlos E, Risueno RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells[J]. Cell，2012，149(6):1284-1297.
|